2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

CANCER PREDISPOSITION IN CHILDHOOD
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Sara Knapke*
Kristin Zelley*
Kim E. Nichols*
Wendy Kohlmann Myriad
Joshua Schiffman*
*No relevant relationships to disclose.
1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American
Cancer Society, 2012.
2. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of
childhood cancer. Br J Cancer. 1991;63:993-999.
3. Pakakasama S, Tomlinson GE. Genetic predisposition and screening in
pediatric cancer. Pediatr Clin North Am. 2002;49:1393-1413.
4. Plon SE, Nathanson K. Inherited susceptibility for pediatric cancer.
Cancer J. 2005;11:255-267.
5. Strahm B, Malkin D. Hereditary cancer predisposition in children:
genetic basis and clinical implications. Int J Cancer. 2006;119:2001-2006.
6. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin
Oncol. 2005;23:276-292.
7. Knapke S, Nagarajan R, Correll J, et al. Hereditary cancer risk assessment
in a pediatric oncology follow-up clinic. Pediatr Blood Cancer. 2012;58:85-89.
8. Schiffman JD. Hereditary cancer syndromes: if you look, you will find
them. Pediatr Blood Cancer. 2012;58:5-6.
9. American Society of Clinical Oncology policy statement update: genetic
testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
10. Eng C, Hampel H, de la Chapelle A. Genetic testing for cancer
predisposition. Annu Rev Med. 2001;52:371-400.
11. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging
surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:
a prospective observational study. Lancet Oncol. 2011;12:559-567.
12. Nichols KE, Malkin D, Garber JE, et al. Germ-line TP53 mutations
predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol
Biomarkers Prev. 2001;10:83-87.
13. Qualman SJ, Bowen J, Erdman SH. Molecular basis of the brain
tumor-polyposis (Turcot) syndrome. Pediatr Dev Pathol. 2003;6:574-576.
14. Royer-Pokora B, Beier M, Henzler M, et al. Am J Med Genet A.
2004;127:249-257.
15. Ruteshouser EC, Huff V. Familial Wilms tumor. Am J Med Genet C
Semin Med Genet. 2004;129C:29-34.
16. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance
TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum
Genet. 1999;65:995-1006.
17. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni
syndrome: clinical characteristics of families with TP53 germline mutations.
J Clin Oncol. 2009;27:1250-1256.
18. Gozali AE, Britt B, Shane L, et al. Choroid plexus tumors; management,
outcome, and association with the Li-Fraumeni syndrome: The Children’s
Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood
Cancer. Epub 2011 Oct 11.
19. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical
subgroups and survival of patients with choroid plexus tumors. J Clin Oncol.
2010;28:1995-2001.
20. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the
Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27:e108-109.
21. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are
frequently detected in young children with rhabdomyosarcoma. J Clin Invest.
1995;95:1606-1611.
22. Calvert G, Randall LR, Jones KB, et al. At risk populations for
osteosarcoma: the syndromes and beyond. Sarcoma. In press.
23. Draper GJ, Sanders BM, Brownbill PA, et al. Patterns of risk of
hereditary retinoblastoma and applications to genetic counseling. Br J
Cancer. 1992;66:211-219.
24. King KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/paraganglioma
related to primary tumor development in childhood or
adolescence: significant link to SDHB mutations. J Clin Oncol. 2011;29:4137-
4142.
25. Schiffman JD. No child left behind in SDHB testing for paragangliomas
and pheochromocytomas. J Clin Oncol. 2011;29:4070-4072.
26. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
Other
Remuneration
INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood
Cancer. 2011;56:7-15.
27. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase
in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
Proc Natl Acad Sci USA.2011;108:314-318.
28. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial
adenomatous polyposis be screened for hepatoblastoma and children with
apparently sporadic hepatoblastoma be screened for APC germline mutations?
Pediatr Blood Cancer. 2006;47:811-818.
29. Dinauer C, Francis GL. Thyroid cancer in children. Endocrinol Metab
Clin North Am. 2007;36:779-806.
30. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma
prevention, risk evaluation, and RET in children of families with MEN2.
J Pediatr Surg. 2007;42:326-332.
31. Walker M, O’Sullivan B, Perakath B, et al. Selecting patients with
young-onset colorectal cancer for mismatch repair gene analysis. Br J Surg.
2007;94:1567-1571.
32. Lwiwski N, Greenberg CR, Mhanni AA. Genetic testing of children at
risk for adult onset conditions: when is testing indicated? J Genet Couns.
2008;17:523-525.
33. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding
leukemogenesis. Cancer Genetics. 2011;204:227-244.
34. Imhof SM, Moll AC, Schouten-van Meeteren AY. Stage of presentation
and visual outcome of patients screened for familial retinoblastoma: nationwide
registration in the Netherlands. Br J Ophthalmol. 2006;90:875-878.
35. Kivelö T. Trilateral retinoblastoma: a meta-analysis of hereditary
retinoblastoma associated with primary ectopic intracranial retinoblastoma.
J Clin Oncol. 1999;17:1829-1837.
36. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome: A molecular
and clinical review. Br J Cancer. 1997;76:1-14.
37. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management
guidelines of the American Thyroid Association. Thyroid. 2009;19:565-
612.
38. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in
multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105-1113.
39. National Comprehensive Cancer Network. Colorectal cancer screening.
NCCN Clinical Practice Guidelines in Oncology. Version 2.2011. www.nccn.
org. Accessed February 6, 2011.
40. Bapat B, Noorani H, Cohen Z, et al. Cost comparisons of predictive
genetic testing versus conventional screening for familial adenomatous polyposis.
Gut. 1999;44:698-703.
41. Boon EM, Keller JJ, Wormhoudt TA, et al. Sulindac targets nuclear
beta-catenin accumulation and Wnt signaling in adenomas of patients with
familial adenomatous polyposis and in human colorectal cancer cell lines.
Br J Cancer. 2004;90:224-229.
42. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a
cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med.
2000;342:1946-1952.
43. Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib
in children with familial adenomatous polyposis. Am J Gastroenterol. 2010;
105:1437-1443.
44. ClinicalTrials.gov. Accessed March 23, 2012.
45. Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic
cancer risk assessment, counseling and testing: updated recommendations of
the National Society of Genetic Counselors. J Genetic Counsel. Epub 2011 Dec
2.
46. Clayton EW. Genetic testing in children. J Med Philos. 1997;22:233-
251.
47. Malpas PJ. Predictive genetic testing of children for adult-onset diseases
and psychological harm. J Med Ethics. 2008;34:275-278.
48. Tischkowitz M, Rosser E. Inherited cancer in children: practical/ethical
problems and challenges. Eur J Cancer. 2004;40:2459-2470.
583